Nabi Biopharmaceuticals Announces Second Quarter 2007 Financi...(logics SBU and expanded the role of Dr. ...),Health

Fahim, Senior Vice President, Research, Technical and Production

Operations to also include Chief Operating Officer and General Manager

of the Biologics SBU

-- Formed the Corporate Shared Services (CSS) group and expanded the role

of Jordan Siegel to Senior Vice President, Finance and Administration,

Chief Financial Officer and Treasurer

July:

-- Formed the Nabi Pharmaceuticals SBU and appointed Dr. Matthew W.

Kalnik Vice President, Business Development and Project Management to

accelerate partnership discussions for Nabi's NicVAX and StaphVAX

programs

-- Reorganized the Nabi employee base to better align with the new

internal structure -- Nabi has eliminated a total of 65 positions and

expects to realize future annualized savings of approximately $6.3

million

-- Completed enrollment in our Anti-D Phase I trial; study completion

expected by end of 2007

Upcoming Milestones

Nabi is currently working toward achieving the following corporate milestones in 2007:

-- Successfully complete the strategic alternatives process with the

support of Banc of America Securities LLC

-- Continue to work to obtain approval for Nabi-HB(R) Intravenous

[Hepatitis B Immune Globulin (Human) Intravenous] in the U.S.;

leverage expertise of Cato Research Ltd.

-- Advance development partnerships for NicVAX and the Gram-positive

programs

-- Continue to provide data from Nabi's ongoing Phase 2b trial of NicVAX

-- Complete enrollment in the 'proof of concept' clinical trial for

Civacir

-- Resubmit the file for regulatory approval of HEBIG(TM) [Hepatitis B

Immune Globulin (Human) Intravenous] in Europe

-- Continue patient recruitment in the Phase 3 trial of ATG-Fresenius S

(anti-T-lymphocyte
'/>"/>

SOURCE Nabi Biopharmaceuticals Copyright©2007 PR Newswire.

0 GOOD